Bone and Renal Safety Are Improved in Chronic HBV Patients 1 Year after Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF)
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San-Francisco, Costa Rica, 9 - 13 November 2018, vol.68, (Summary Text)
